CANF
Can-fite BiopharmaยทAMEX
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
CANF Profile
Can-Fite Biopharma Ltd.
A company that developing small molecule therapeutics to treat autoimmune-inflammatory, oncological and ophthalmic diseases
Pharmaceutical
09/11/1994
11/19/2013
American Stock Exchange
5
12-31
Depository Receipts (Ordinary Shares)
26 Ben Gurion Street, Ramat Gan, 5257346, Israel
Advanced clinical-stage biopharmaceutical company.
Can-fite Biopharma Ltd., was founded on September 11, 1994. The Company is an advanced clinical-stage biopharmaceutical company developing oral bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein-associated A3 adenosine receptor, or A3AR, as a therapeutic target. A3AR is highly expressed in pathological somatic cells such as inflammation and cancer cells, and low in normal cells, suggesting that this receptor may be a specific target for pharmacological intervention. The company's pipeline of drug candidates are synthetic, highly specific agonists and allosteric modulators targeting A3AR.
